When depression has persisted through medication changes, therapy, and genuine effort, being told to “try another antidepressant” can feel defeating. Understanding how to qualify for Spravato treatment can give you a clearer path forward – not a promise of a cure, but a medically supervised option designed for certain adults whose depression has not responded adequately to standard care.
Spravato is the brand name for esketamine, a prescription nasal spray used alongside an oral antidepressant. It is not the same as a take-home nasal spray or a standard antidepressant prescription. Because it can cause short-term sedation, dissociation, and changes in blood pressure, it is administered in a certified healthcare setting under a federally required safety program.
Who May Qualify for Spravato Treatment?
The most common reason a clinician considers Spravato is treatment-resistant depression, often called TRD. In practical terms, this generally means a person has major depressive disorder and has not experienced adequate improvement after trying at least two antidepressant medications at appropriate doses and for an appropriate length of time during the current depressive episode.
That definition is clinically important, but it is not the whole story. A qualified provider will look at the quality of prior medication trials, not simply the number of prescriptions listed in a medical record. A medication may not count as an adequate trial if it was stopped very early because of side effects, taken inconsistently, or never titrated to a therapeutic dose. On the other hand, intolerable side effects are real and relevant. The goal is not to make someone endure medications that make them feel worse. It is to understand what has been tried and what has or has not helped.
Spravato is also approved, when used with an oral antidepressant, for adults with major depressive disorder who have acute suicidal thoughts or behaviors. This is a serious clinical situation that requires prompt evaluation and a broader safety plan. Spravato may be one part of care, but it does not replace crisis support, psychiatric follow-up, or emergency intervention when immediate danger is present.
A diagnosis of depression alone does not automatically establish eligibility. Your provider must determine that Spravato is appropriate for your symptoms, health history, current medications, and treatment goals.
What Your Initial Evaluation Should Cover
A thoughtful Spravato evaluation is more than a quick screening questionnaire. At Quad Cities Ketamine Clinic, the conversation should begin with what your depression has actually been like: how long it has lasted, how it affects sleep, work, relationships, concentration, motivation, and your ability to enjoy daily life.
Your clinician will typically review your mental health diagnosis, prior antidepressants, therapy history, current psychiatric medications, substance use history, and any previous response to ketamine or other advanced treatments. They may also ask about anxiety, trauma, chronic pain, migraines, and medical conditions that can complicate mood symptoms or influence treatment planning.
Medical screening matters because Spravato can temporarily raise blood pressure. Before treatment, the care team needs to know about high blood pressure, heart or vascular conditions, liver disease, pregnancy status, and all medications or supplements you take. This includes stimulants, sedatives, opioids, and medications that may affect blood pressure or alertness.
Your provider will also assess for bipolar disorder, psychosis, and active substance use concerns. These do not always lead to an automatic no, but they require careful clinical judgment. For example, a history of mania may change the treatment plan because any antidepressant-focused approach needs to account for mood destabilization risk.
Medical Conditions That May Rule Out Spravato
Some conditions require particular caution, while others are formal reasons Spravato should not be used. Spravato is contraindicated for people with aneurysmal vascular disease, including certain aneurysms, arteriovenous malformations, or a history of intracerebral hemorrhage. These conditions can make a temporary increase in blood pressure especially unsafe.
Uncontrolled hypertension may also delay treatment until blood pressure is better managed. This does not mean everyone with high blood pressure is excluded. Many people can be considered once their condition is stable and their prescribing team agrees that treatment can be delivered safely.
Pregnancy and breastfeeding require an individualized conversation with an appropriate medical provider. People with a history of substance misuse may still be evaluated, but the clinician will carefully weigh benefits, risks, monitoring needs, and the availability of supportive care. Being candid is essential. The safest plan is built on accurate information, not on giving the answers you think a clinic wants to hear.
Why Spravato Requires In-Clinic Monitoring
One part of qualifying for Spravato treatment is being willing and able to follow its monitoring requirements. Spravato is dispensed and administered through the Spravato REMS program, a safety program designed to reduce risk during and after dosing.
Each treatment visit includes blood pressure checks and observation by trained clinical staff. Patients remain at the clinic for at least two hours after administration so the team can monitor for sedation, dissociation, dizziness, nausea, or blood pressure changes. Dissociation may feel like a temporary sense of detachment from your thoughts, body, or surroundings. It can be unsettling for some patients, which is one reason a calm, supportive setting and attentive staff matter.
You cannot drive yourself home after a Spravato appointment. You will need a responsible adult to drive you or another safe transportation arrangement. You should also plan not to drive, operate machinery, or make important decisions until the next day after a restful night of sleep.
These expectations are not administrative details. They are part of safe care. A provider may determine that a patient is clinically eligible but ask them to delay starting until transportation, scheduling, or support needs are in place.
What Treatment Resistance Looks Like in Real Life
Treatment-resistant depression does not always look dramatic from the outside. It may look like getting through work while feeling emotionally absent. It may look like withdrawing from family, losing interest in activities you once loved, or feeling exhausted by the effort of appearing fine.
Some people have tried several medications with little benefit. Others have found partial relief but continue to struggle with persistent low mood, hopelessness, impaired concentration, or recurring depressive episodes. Therapy remains valuable, but therapy and medication can both be in place while symptoms continue to interfere with life.
Spravato is not necessarily the first advanced option for every person with depression. Some patients may benefit from an adjustment to conventional medication management, psychotherapy, sleep treatment, hormone or nutritional evaluation, transcranial magnetic stimulation, or another approach. The right next step depends on your diagnosis, prior care, medical history, and preferences.
Insurance Approval and Clinical Qualification Are Different
A clinician may decide that Spravato is medically appropriate, while an insurance plan may have separate coverage requirements. Many insurers ask for documentation of major depressive disorder, inadequate response to prior antidepressant trials, concurrent use of an oral antidepressant, and treatment through a REMS-certified site.
Coverage criteria vary by plan and can change over time. A clear medication history helps. If possible, gather the names of prior medications, approximate dates, doses, prescribing clinicians, side effects, and whether each medication helped. Records from a psychiatrist, primary care clinician, or therapist can also help your care team understand the full course of your depression.
For patients paying out of pocket or using financing, the clinical screening remains just as important. Financial access does not replace medical appropriateness, and a responsible clinic will not recommend treatment simply because it is available.
Preparing for Your Spravato Consultation
Come prepared to talk openly about your symptoms and what you have already tried. Bring a current medication list and relevant medical records if you have them. If you are unsure of past medication details, your pharmacy or former prescriber may be able to help reconstruct that history.
It also helps to think through logistics before starting. Spravato treatment usually involves more frequent visits at the beginning, followed by a maintenance schedule based on response and clinical need. Ask how visits are structured, how progress is measured, what happens if side effects occur, and how Spravato fits with your existing therapist or prescribing clinician.
The most useful question is not simply, “Do I qualify?” It is, “Is this a safe and appropriate next step for me?” A careful evaluation can answer that question with the nuance it deserves – and help you move toward care that recognizes both the seriousness of depression and the possibility of meaningful relief.
